Günther Steger

10.4k total citations
69 papers, 2.2k citations indexed

About

Günther Steger is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Günther Steger has authored 69 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 24 papers in Cancer Research and 14 papers in Molecular Biology. Recurrent topics in Günther Steger's work include Breast Cancer Treatment Studies (22 papers), HER2/EGFR in Cancer Research (18 papers) and Cancer Treatment and Pharmacology (18 papers). Günther Steger is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), HER2/EGFR in Cancer Research (18 papers) and Cancer Treatment and Pharmacology (18 papers). Günther Steger collaborates with scholars based in Austria, United States and Germany. Günther Steger's co-authors include Robert M. Mader, R. Jakesz, Michael Gnant, Richard Greil, Brigitte Mlineritsch, Christoph Zielinski, Florian Fitzal, Christian F. Singer, Susanne Taucher and Markus Müller and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Günther Steger

69 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Günther Steger Austria	27	1.6k	660	485	424	411	69	2.2k
José Á. García-Sáenz Spain	29	2.1k 1.3×	1.0k 1.5×	631 1.3×	1.0k 2.5×	316 0.8×	162	3.0k
Kenjiro Aogi Japan	28	1.7k 1.0×	818 1.2×	521 1.1×	573 1.4×	434 1.1×	150	2.9k
J. Thaddeus Beck United States	19	1.4k 0.8×	619 0.9×	551 1.1×	740 1.7×	185 0.5×	74	2.1k
Carla I. Falkson United States	26	1.8k 1.1×	797 1.2×	811 1.7×	528 1.2×	316 0.8×	95	2.8k
Suhail M. Ali United States	26	1.3k 0.8×	389 0.6×	542 1.1×	296 0.7×	583 1.4×	78	1.9k
Georgiana K. Ellis United States	27	1.3k 0.8×	1.1k 1.6×	359 0.7×	562 1.3×	1.5k 3.7×	54	3.0k
Toshimi Takano Japan	25	2.1k 1.3×	616 0.9×	628 1.3×	1.7k 3.9×	256 0.6×	172	3.0k
Roberto Petrioli Italy	28	1.6k 1.0×	407 0.6×	508 1.0×	1.2k 2.9×	246 0.6×	135	3.1k
Hans‐Joachim Lück Germany	28	1.9k 1.1×	721 1.1×	395 0.8×	572 1.3×	298 0.7×	67	2.9k
Suneel Mundle United States	28	560 0.3×	638 1.0×	913 1.9×	1.5k 3.6×	526 1.3×	131	3.3k

Countries citing papers authored by Günther Steger

Since Specialization

Citations

This map shows the geographic impact of Günther Steger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Günther Steger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Günther Steger more than expected).

Fields of papers citing papers by Günther Steger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Günther Steger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Günther Steger. The network helps show where Günther Steger may publish in the future.

Co-authorship network of co-authors of Günther Steger

This figure shows the co-authorship network connecting the top 25 collaborators of Günther Steger. A scholar is included among the top collaborators of Günther Steger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Günther Steger. Günther Steger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wimmer, Kerstin, Dominik Hlauschek, Marija Balić, et al.. (2024). Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?. Breast Cancer Research and Treatment. 205(2). 227–239. 1 indexed citations

Matikas, Alexios, Andri Papakonstantinou, Sibylle Loibl, et al.. (2024). Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial. The Lancet Regional Health - Europe. 49. 101162–101162. 2 indexed citations

Rössler, Fabian, Martina Mittlböck, Nicolas Kozakowski, et al.. (2020). Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 477(4). 545–555. 6 indexed citations

Gnant, Michael, Georg Pfeiler, Günther Steger, et al.. (2019). Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 20(3). 339–351. 152 indexed citations

Kiesewetter, Barbara, Markus Raderer, Günther Steger, et al.. (2016). The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open. 1(4). e000066–e000066. 17 indexed citations

Promberger, Regina, Peter Dubsky, Martina Mittlböck, et al.. (2015). Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. Clinical Breast Cancer. 15(6). 505–511. 3 indexed citations

Körber, Maria Isabel, et al.. (2013). NF-?B addiction and resistance to 5-fluorouracil in a multi-stage colon carcinoma model. International Journal of Clinical Pharmacology and Therapeutics. 51(1). 35–37. 5 indexed citations

Láng, István, Thomas Brodowicz, Larisa Ryvo, et al.. (2013). Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. The Lancet Oncology. 14(2). 125–133. 60 indexed citations

Tausch, Christoph, Günther Steger, A. Haid, et al.. (2011). Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14. The Breast Journal. 17(3). 230–238. 5 indexed citations

10.

Greil, Richard, Simona Borštnar, Katarína Petráková, et al.. (2011). Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe. Onkologie. 34(5). 233–238. 7 indexed citations

11.

Petru, Edgar, Johannes Andel, Günther Steger, et al.. (2008). Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. Wiener Medizinische Wochenschrift. 158(5-6). 169–173. 6 indexed citations

12.

Steger, Günther, et al.. (2007). Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro. Cancer Letters. 257(1). 73–78. 6 indexed citations

13.

Fitzal, Florian, O Riedl, Wolfgang Draxler, et al.. (2007). Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. Breast Cancer Research and Treatment. 103(1). 45–52. 16 indexed citations

14.

Köstler, Wolfgang J., Günther Steger, Afschin Soleiman, et al.. (2004). Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.. PubMed. 24(2C). 1127–30. 25 indexed citations

15.

Brostjan, Christine, R. Roka, R. Jakesz, et al.. (2003). Monitoring of circulating angiogenic factors in dendritic cell–based cancer immunotherapy. Cancer. 98(10). 2291–2301. 17 indexed citations

16.

Holub, Margareta, Cornelia Lichtenberger, Johannes Pammer, et al.. (2003). Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology. 15(2). 119–126. 7 indexed citations

17.

Müller, Markus, et al.. (2000). Relationship between in vivo drug exposure of the tumor interstitium and inhibition of tumor cell growth in vitro: a study in breast cancer patients. Breast Cancer Research and Treatment. 60(3). 211–217. 18 indexed citations

18.

Brodowicz, Thomas, Christoph Wiltschke, Alexandra C. Budinsky, et al.. (1997). Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cellsin vitro. International Journal of Cancer. 73(6). 875–879. 66 indexed citations

19.

Mader, Robert M., et al.. (1996). Exposure of Oncologic Nurses to Methotrexate in the Treatment of Osteosarcoma. Archives of Environmental Health An International Journal. 51(4). 310–314. 35 indexed citations

20.

Locker, Gottfried J., Robert M. Mader, Anna E. Sieder, et al.. (1995). New Mucin-Like Cancer-Associated Antigens (CA M 26, CA M 29 and CA 549) and a New Proliferation Marker (TPS) in Patients with Primary or Advanced Breast Cancer. Oncology. 52(2). 140–144. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact